Unit:
Τομέας ΠαθολογίαςLibrary of the School of Health Sciences
Author:
Αλεξιάδου Κλεοπάτρα
Dissertation committee:
Καθηγητής Σ. Λαδάς, Αναπληρωτής Καθηγητής Ν. Τεντολούρης, Αναπληρωτής Καθηγητής Κ. Μακρυλάκης
Original Title:
Σύγκριση της επίδρασης της σιταγλιπτίνης και της μετφορμίνης στα επίπεδα των πεπτιδίων που ρυθμίζουν την όρεξη σε ασθενείς με διαβήτη τύπου 2
Summary:
SUMMARY
Objective: To investigate the effect of sitagliptin and metformin on the gut
peptide levels and on the glucose and lipid profiles in patients with type 2
diabetes.
Materials and methods: Thirty one patients with newly diagnosed type 2 diabetes
participated in this study and were allocated to two groups. One group [mean
age: 59.5 ± 10.5 years, BMI: 33.4 ± 6.1 kg/m²] was started on metformin (850 mg
daily) and the other group [mean age: 58.1 ± 7.9 years, BMI: 31.8 ± 8.1 kg/m²]
was started on sitagliptin (100 mg daily) for four weeks. Patients received a
test meal of mixed content and caloric value of 697 Kcal after an overnight
fast, at baseline and four weeks after the treatment. The levels of ghrelin,
GLP-1, GIP, PYY, insulin and glucose were measured before the meal initiation
and 30, 60, 90, 120, 180, 240, 300, 360 minutes post-prandially. Lipid levels
were measured at fasting state and 2, 4 and 6 hours post-prandially.
Results: There was a significant reduction of glycated haemoglobin in both
study groups four weeks after treatment initiation. In the metformin group,
fasting HDL-C was higher at week 4. In the sitagliptin group, fasting glucose
levels were significantly lower while fasting PYY and GLP-1 levels were
significantly higher four weeks after treatment initiation.
In the metformin group, there was a trend for higher post-prandial levels of
HDL-C and lower post-prandial levels of insulin at week 4. In the sitagliptin
group, there was a trend for lower post-prandial glucose levels while the
post-prandial levels of HDL-C and GLP-1 were significantly higher at week 4.
The two study groups displayed statistically significant difference in the
post-prandial levels of GLP-1 four weeks after treatment initiation.
Conclusion: Both sitagliptin and metformin are equally effective on fasting and
post-prandial glucose control since they exert similar effect on the values of
glycated haemoglobin in patients with type 2 diabetes. The administration of
sitagliptin results in lower fasting glucose levels and higher post-prandial
levels of HDL-C as well as in higher levels of fasting PYY and both fasting and
postprandial GLP-1 compared to the administration of metformin four weeks after
the treatment initiation.
Keywords:
Sitagliptin, Metformin, Incretins, GLP-1, PYY
Number of references:
452
File:
File access is restricted only to the intranet of UoA.
document.pdf
1 MB
File access is restricted only to the intranet of UoA.
